Scott Requadt, JD, MBA, is the CEO of Talaris Therapeutics and serves on the Board of Directors. Scott has over 20 years of operating and investment experience in the biopharmaceutical industry. He currently serves on the Board of Directors of ESSA Pharmaceuticals (Nasdaq: EPIX), and previously served on the Boards of Edev S.a.r.l., Avrobio (Nasdaq: AVRO), VBI Vaccines (Nasdaq: VBIV) and TyRx, Inc. Scott remains a Venture Partner advisor to Blackstone Life Sciences. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired by Johnson & Johnson. Prior to TransForm, Scott was an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance) from McGill University (First Class Honors), a J.D. from University of Toronto and an MBA from Harvard Business School, where he was a Baker Scholar.